Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps ; volume:41 ; number:05 ; year:2020 ; pages:733-734
Indian journal of medical & paediatric oncology ; 41, Heft 05 (2020), 733-734
- Beteiligte Personen und Organisationen
-
Singh, Suvir
- DOI
-
10.4103/ijmpo.ijmpo_275_20
- URN
-
urn:nbn:de:101:1-2021082712024825163695
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Singh, Suvir
Ähnliche Objekte (12)
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease
Small steps for workers, a giant leap for productivity
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
The Leap (No Leap)
Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Leap year
Leap Next
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease
Small steps for workers, a giant leap for productivity
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
The Leap (No Leap)
Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Leap year
Leap Next
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease
Small steps for workers, a giant leap for productivity
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
The Leap (No Leap)
Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Leap year
Leap Next